Purpose of Review

It has been firmly established that hexaminolevulinate-assisted blue light cystoscopy (HAL-BLC) reduces cancer recurrence rates. This review explores the impact of HAL-BLC on other meaningful outcomes in patients with bladder cancer, including disease progression, and earlier detection of disease at the time of surveillance cystoscopy.

Recent Findings

A randomized clinical trial confirmed earlier implementation of HAL-BLC at the time of surveillance cystoscopy increased identification of cancerous lesions, including those of high grade, when compared with white light cystoscopy. In addition, the evidence is evolving that the use of HAL-BLC at the time of endoscopic treatment of high-risk tumors may lead to lower rates of progression to muscle invasion, and this in part may be due to better risk stratification leading to changes in treatment plan.

Summary

The clinical contexts for the use of HAL-BLC are broader than prior knowledge. It is also becoming more clear that the positive impact of HAL-BLC is likely more than just reducing cancer recurrence rates, and patients would benefit from the technology at many time points in the management and follow-up of their disease.

中文翻译：

---

蓝光膀胱镜检查：适应症和结果。

审查目的

牢固地确定了六乙酰基乙酰丙酸盐辅助的蓝光膀胱镜检查（HAL-BLC）可降低癌症的复发率。这篇综述探讨了HAL-BLC对膀胱癌患者其他有意义结局的影响，包括疾病进展以及在监测性膀胱镜检查时及早发现疾病。

最近的发现

一项随机临床试验证实，与白光膀胱镜检查相比，在监视性膀胱镜检查时更早实施HAL-BLC可以提高对癌症病变（包括高级别癌变）的识别率。此外，越来越多的证据表明，在内镜治疗高危肿瘤时使用HAL-BLC可能会导致肌肉浸润的发生率降低，这部分是由于更好的风险分层导致变化在治疗计划中。

概要

使用HAL-BLC的临床环境比现有知识要广泛。越来越清楚的是，HAL-BLC的积极影响可能不仅仅是降低癌症的复发率，而且患者将在疾病管理和随访的许多时间受益于该技术。